Literature DB >> 31167735

Metastatic cholangiocarcinoma in a patient with undiagnosed Wilson disease.

Marianna G Mavilia1, Aniket Sharma2, Faripour Forouhar3.   

Abstract

Cholangiocarcinoma (CC) is the second most common primary hepatic malignancy. Although the frequency of malignancy is generally increased in chronic liver disease, CC rarely presents in Wilson disease (WD). The incidence of hepatic malignancy in WD is only 1.2%, with CC accounting for 0.5%. A 66 year old male with history of hypertension, diabetes, and compensated cryptogenic cirrhosis presented with acute onset dyspnea and pleuritic chest pain. He was incidentally found to have a sizeable mass in the right hepatic lobe. Ultimately, a liver biopsy revealed dense demoplasia and increased mucin production, consistent with diagnosis of CC. Biopsy also demonstrated increased copper deposition consistent with WD, explaining the patient's underlying cirrhosis. Unlike other forms of chronic liver disease where incidence of liver cancer is increased, the lower rate of malignancy seen in WD may be explained by a protective effect of copper in WD. Copper acts to both directly stabilize DNA and inhibit angiogenesis. In this case, it is possible that the degree of copper deposition in his liver was mild, causing cirrhosis and the chronic liver inflammation that caused his CC. However, it may not have been sufficient to "protect" against development of CC.
Copyright © 2019. Published by Elsevier España, S.L.U.

Entities:  

Keywords:  Cirrhosis; Copper; Hepatic malignancy

Year:  2019        PMID: 31167735     DOI: 10.1016/j.aohep.2019.04.016

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  1 in total

1.  Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster.

Authors:  Giovanni Brandi; Alessandro Rizzo; Marzia Deserti; Valeria Relli; Valentina Indio; Sofia Bin; Milena Pariali; Andrea Palloni; Stefania De Lorenzo; Francesco Tovoli; Simona Tavolari
Journal:  BMC Med Genet       Date:  2020-11-18       Impact factor: 2.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.